The Europe glaucoma therapeutics market was valued at US$ 1,529.83 million in 2023 and is expected to reach US$ 1,930.78 million by 2031; it is estimated to register a CAGR of 3.0% from 2023 to 2031.
Increasing Number of Product Launches, Collaborations, and Acquisitions Fuels Europe Glaucoma Therapeutics Market
Glaucoma therapeutics manufacturers are implementing strategies such as strategic alliances, geographic expansions, partnerships, mergers & acquisitions, and product/service launches to mark their presence in the market.
Such product launches, collaborations, and acquisitions contribute significantly to the growth of the glaucoma therapeutics market.
Europe Glaucoma Therapeutics Market Overview
The Europe glaucoma therapeutics market is segmented into Germany, France, the UK, Spain, Italy, and the Rest of Europe. Countries such as Germany and Italy contribute significant shares to the market in this region, and countries such as France, the UK, and Spain are likely to present significant growth opportunities for glaucoma therapeutics market players. The Europe glaucoma therapeutics market growth is ascribed to the rising number of glaucoma cases with the increasing aging population. Germany records a widespread occurrence of glaucoma. According to Sabel Vision Restoration Center (SAVIR), approximately half a million people are affected by glaucoma in this country. However, experts estimate that the actual number may be much higher due to unreported cases. Nearly 10% of all individuals suffering from glaucoma eventually experience serious vision impairments; nonetheless, almost none is likely to attain complete blindness. As per the Federal Statistical Office (Destatis), 16.2 million people in Germany were aged 67 and above by the end of 2021, and the number is projected to rise to 21.6 million by 2060. The probability of developing glaucoma and other eye diseases is likely to increase with aging. Thus, a significant prevalence of glaucoma due to the surging geriatric population propels the demand for glaucoma therapeutics across Germany.
Europe Glaucoma Therapeutics Market Revenue and Forecast to 2031 (US$ Million)
Europe Glaucoma Therapeutics Market Segmentation
The Europe glaucoma therapeutics market is categorized into drug class, indication, distribution channel, and country.
Based on drug class, the Europe glaucoma therapeutics market is segmented into beta blockers, alpha adrenergic agonists, prostaglandins analogues, carbonic anhydrase inhibitors, combination drugs, and others. The prostaglandins analogues segment held the largest market share in 2023.
In terms of indication, the Europe glaucoma therapeutics market is categorized into open angle glaucoma, angle closure glaucoma, and others. The open angle glaucoma segment held the largest market share in 2023.
By distribution channel, the Europe glaucoma therapeutics market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment held the largest market share in 2023.
By country, the Europe glaucoma therapeutics market is segmented into Germany, France, Italy, the UK, Spain, and the Rest of Europe. Germany dominated the Europe glaucoma therapeutics market share in 2023.
Alcon AG, AbbVie Inc, Bausch & Lomb Inc, LLC, Viatris Inc, Novartis AG, Sun Pharmaceutical Industries Ltd, Teva Pharmaceuticals Industries Ltd, Thea Pharma Inc, and Santen Pharmaceutical Co., Ltd. are among the leading companies operating in the Europe glaucoma therapeutics market.
| Report Attribute | Details |
|---|---|
| Market size in 2023 | US$ 1,529.83 Million |
| Market Size by 2031 | US$ 1,930.78 Million |
| CAGR (2023 - 2031) | 3.0% |
| Historical Data | 2021-2023 |
| Forecast period | 2025-2031 |
| Segments Covered |
By Drug Class
|
| Regions and Countries Covered |
Europe
|
| Market leaders and key company profiles |
|
The Europe Glaucoma Therapeutics Market is valued at US$ 1,529.83 Million in 2023, it is projected to reach US$ 1,930.78 Million by 2031.
As per our report Europe Glaucoma Therapeutics Market, the market size is valued at US$ 1,529.83 Million in 2023, projecting it to reach US$ 1,930.78 Million by 2031. This translates to a CAGR of approximately 3.0% during the forecast period.
The Europe Glaucoma Therapeutics Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Glaucoma Therapeutics Market report:
The Europe Glaucoma Therapeutics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Glaucoma Therapeutics Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Glaucoma Therapeutics Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Europe Glaucoma Therapeutics Market
